Executive Vice President and Chief Commercial Officer · RIGEL PHARMACEUTICALS INC (RIGL)

David Santos

A named executive officer of RIGEL PHARMACEUTICALS in every fiscal year CompBrief holds from FY2020 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$1,831,604

FY2024: $1,382,463

2nd of 5 named executive officers at Rigel Pharmaceuticals by FY2025 total.

5 named officers on file for RIGEL PHARMACEUTICALS, FY2025

See an example →

What this number hides

The filing gives the total. RIGEL PHARMACEUTICALS’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Compensation figures as of the proxy filed April 3, 2026 (DEF 14A). Insider transactions since that proxy, current to 2026-11-07.

Free

Get David Santos’s full pay file as a PDF — free

More than this page: up to 10 years of David’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track David Santos and every company like it: Velarion Intel, free for 3 days, no card →

David Santos compensation by year

RIGEL PHARMACEUTICALS Summary Compensation Table · all 6 fiscal years held
In US dollars, as RIGEL PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022FY2023FY2024FY2025
Salary$163,726$425,375$450,000$477,000$496,080$515,920
Bonus$0$0$0$0$0$0
Stock awards$0$0$121,000$149,600$265,430$443,435
Option awards$155,625$641,328$321,780$455,008$307,500$522,844
Non-equity incentive$819,854$169,087$204,525$230,153$277,805$308,830
Pension and deferred compensation$0$0$0$0$0$0
All other$51,397$6,175$27,110$30,030$35,648$40,575
Total$1,190,602$1,241,965$1,124,415$1,341,791$1,382,463$1,831,604

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: RIGEL PHARMACEUTICALS INC DEF 14A filed April 3, 2026, accession 0001034842-26-000023, and prior-year filings. Open the filing on EDGAR.

How this page was built: the RIGEL PHARMACEUTICALS INC filed document, accession 0001034842-26-000023. Every figure is read from that document and cited to the page and table it appears in. Filed April 3, 2026.

$1.2M
$1.2M
$1.1M
$1.3M
$1.4M
$1.8M
FY20
FY21
FY22
FY23
FY24
FY25
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU19,717$844,479—
RSU13,934$596,793—
RSU4,000$171,320—
RSU1,250$53,538—
Option4,333—$18.70
Option10,270—$22.49
Option5,671—$12.70
Option212—$24.20

Per the Outstanding Equity Awards at Fiscal Year-End table in RIGEL PHARMACEUTICALS INC's FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

3 Form 4 lines since the FY2025 proxy (filed April 3, 2026)
current to 2026-11-07 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-09-01Tax withholding—874$47.5061,622
2026-06-17Grant or award derivative—7,394$0.007,394
2026-06-01Tax withholding—874$29.8661,996

The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

RIGEL PHARMACEUTICALS’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Raul RodriguezPresident and Chief Executive Officer$4,658,805
David Santos · this pageExecutive Vice President and Chief Commercial Officer$1,831,604
Lisa RojkjaerExecutive Vice President and Chief Medical Officer$1,830,175
Dean SchornoExecutive Vice President and Chief Financial Officer$1,822,409
Raymond FureyExecutive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary$1,769,502

The full RIGEL PHARMACEUTICALS compensation record

free company brief

This page is one person within RIGEL PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the RIGEL PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order RIGEL PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are RIGEL PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order RIGL

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

David Santos's compensation dossier